Baxdrostat(CIN-107) is a selective and potent inhibitor of aldosterone synthase(CYP11B2), a rate-limiting enzyme in the pathway of aldosterone synthesis, with the potential to treat resistant hypertension. It also inhibits the function of multidrug and toxin extrusion 1 (MATE1) and MATE2-K with IC50 values of 1.34 µM and 2.67 µM, respectively.

Baxdrostat(CIN-107) is a selective and potent inhibitor of aldosterone synthase(CYP11B2), a rate-limiting enzyme in the pathway of aldosterone synthesis, with the potential to treat resistant hypertension. It also inhibits the function of multidrug and toxin extrusion 1 (MATE1) and MATE2-K with IC50 values of 1.34 µM and 2.67 µM, respectively.

ECC5004(AZD5004, GLP-1 agonist (Eccogene)) is a small molecule GLP-1 receptor agonist (GLP-1RA) used to treat digestive system diseases and endocrine and metabolic diseases. ECC5004 has the potential to be used to treat obesity, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH) disease.

ECC5004(AZD5004, GLP-1 agonist (Eccogene)) is a small molecule GLP-1 receptor agonist (GLP-1RA) used to treat digestive system diseases and endocrine and metabolic diseases. ECC5004 has the potential to be used to treat obesity, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH) disease.

ECC5004(AZD5004, GLP-1 agonist (Eccogene)) is a small molecule GLP-1 receptor agonist (GLP-1RA) used to treat digestive system diseases and endocrine and metabolic diseases. ECC5004 has the potential to be used to treat obesity, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH) disease.

ECC5004(AZD5004, GLP-1 agonist (Eccogene)) is a small molecule GLP-1 receptor agonist (GLP-1RA) used to treat digestive system diseases and endocrine and metabolic diseases. ECC5004 has the potential to be used to treat obesity, type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH) disease.

7rh (DDR1-IN-2) is a potent inhibitor of discoidin domain receptor 1 (DDR1) with an IC50 of 13.1 nM. It also inhibits DDR2 less effectively with an IC50 of 203 nM. It also exhibits antitumor effects in nasopharyngeal carcinoma cells.

Vazegepant hydrochloride (BHV-3500, Zavegepant), is a highly potent, selective, and structurally unique small molecule antagonist of CGRP receptor. It can also be used for the acute treatment of migraine.

Vazegepant hydrochloride (BHV-3500, Zavegepant), is a highly potent, selective, and structurally unique small molecule antagonist of CGRP receptor. It can also be used for the acute treatment of migraine.

Vazegepant hydrochloride (BHV-3500, Zavegepant), is a highly potent, selective, and structurally unique small molecule antagonist of CGRP receptor. It can also be used for the acute treatment of migraine.